Hijazi, Sameh

[["dc.bibliographiccitation.firstpage","31"],["dc.bibliographiccitation.journal","International Journal of Women's Health"],["dc.contributor.author","Hijazi, Sameh"],["dc.contributor.author","Leitsmann, Conrad"],["dc.date.accessioned","2021-06-01T10:48:33Z"],["dc.date.available","2021-06-01T10:48:33Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.2147/IJWH.S94956"],["dc.identifier.eissn","1179-1411"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85973"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1179-1411"],["dc.title","Clinical significance of video-urodynamic in female recurrent urinary tract infections"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","66"],["dc.bibliographiccitation.journal","EJNMMI Research"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Hijazi, Sameh"],["dc.contributor.author","Bouter, Caroline"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Thelen, Paul"],["dc.date.accessioned","2018-11-07T09:48:52Z"],["dc.date.available","2018-11-07T09:48:52Z"],["dc.date.issued","2015"],["dc.description.abstract","Background: Prostate-specific membrane antigen (PSMA) is a promising target for diagnostics and therapy of prostate carcinoma (PCa). Based on the hypothesis that PSMA expression can be modulated by variations in androgen deprivation therapy (ADT), we investigated the binding of a PSMA-directed radiopharmaceutical in vitro in order to get an insight of the interactions between altered premedication and PSMA expression before repetitive PSMA-directed PET/CT for therapy response and targeted therapy implementation. Methods: The human castration-resistant PCa cell line VCaP (CRPC) was treated with either 1 nmol/L testosterone (T) over 20 passages yielding the androgen-sensitive cell line (revCRPC) or with 5 mu mol/L abiraterone acetate (AA) generating the abiraterone-tolerant subtype CRPCAA. In these cell lines, T and AA were varied by either supply or withdrawal of T and AA. PSMA expression of the three cell culture models was detected by Western blot and immunohistochemical staining. For quantitative measurement of tracer uptake, 0.3 nmol/L Ga-68-labelled PSMA-HBED-CC peptide (100-300 kBq/ml) was added to different treated parallel cultures (n = 9 each). Time-dependent uptake per 10(6) cells of each culture was calculated and evaluated. PSMA mRNA expression was investigated by qPCR. Results: PSMA expression increased dependently on intensified ADT in all three basic cell lines. Ga-68-PSMA-HBED-CC uptake almost doubled during 3 h in all cell lines (p < 0.01). Compared to the basic cells, pre-incubation with abiraterone for 48 h resulted in a significant increased uptake in CRPC (p < 0.001). In revCRPC, 48-h AA pre-incubation resulted in an eightfold higher uptake after 3 h (p < 0.001). Additional withdrawal of external testosterone increased the uptake up to tenfold (p < 0.01). The increase of PSMA expression upon ADT and AA treatments was confirmed by qPCR and Western blot data. Furthermore, in CRPCAA, 48-h AA withdrawal increased the uptake up to fivefold (p < 0.01). Conclusions: The investigated three PCa cell culture subtypes represent a serial preclinical model of androgen deprivation therapy as a proxy for clinical situations with differing basal PSMA expression. The uptake of PSMA-binding tracers could be stimulated by therapeutic effective short-term variation in premedication in all stages of ADT response. These complex interactions have to be considered in the interpretation of diagnostic imaging using PSMA ligands as well as in the optimal timing of PSMA-based therapies."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft DFG [TH 389/3-1, BR4700/1-1]"],["dc.identifier.doi","10.1186/s13550-015-0145-8"],["dc.identifier.isi","000364963600001"],["dc.identifier.pmid","26576996"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12584"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35393"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","2191-219X"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","66"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Urology Annals"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Hijazi, Sameh"],["dc.contributor.author","Echtle, Dieter"],["dc.contributor.author","Hasselhof, ViktoriaM"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Heinrich, Elmar"],["dc.date.accessioned","2020-12-10T18:47:43Z"],["dc.date.available","2020-12-10T18:47:43Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.4103/0974-7796.163795"],["dc.identifier.issn","0974-7796"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78862"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Metal telescopic and Amplatz sheath dilation in nephrolithotomy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S163"],["dc.bibliographiccitation.journal","European Journal of Nuclear Medicine and Molecular Imaging"],["dc.bibliographiccitation.lastpage","S164"],["dc.bibliographiccitation.volume","42"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Hijazi, Sameh"],["dc.contributor.author","Bouter, Caroline"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Thelen, Paul"],["dc.date.accessioned","2018-11-07T09:50:50Z"],["dc.date.available","2018-11-07T09:50:50Z"],["dc.date.issued","2015"],["dc.identifier.isi","000363013201287"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35785"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.conference","28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM)"],["dc.relation.eventlocation","Hamburg, GERMANY"],["dc.relation.issn","1619-7089"],["dc.relation.issn","1619-7070"],["dc.title","Increase of PSMA Expression by Androgen Deprivation"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","625"],["dc.bibliographiccitation.journal","International Journal of Women's Health"],["dc.bibliographiccitation.lastpage","630"],["dc.bibliographiccitation.volume","Volume 9"],["dc.contributor.author","Hijazi, Sameh"],["dc.contributor.author","Echtle, Dieter"],["dc.contributor.author","Aboumarzouk, Omar M"],["dc.contributor.author","Heinrich, Elmar"],["dc.date.accessioned","2021-06-01T10:48:32Z"],["dc.date.available","2021-06-01T10:48:32Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.2147/IJWH.S134239"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85972"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1179-1411"],["dc.title","Abdominal sacrocolpopexy with Pelvicol xenograft and concomitant Burch colposuspension"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1934"],["dc.bibliographiccitation.issue","16"],["dc.bibliographiccitation.journal","The Prostate"],["dc.bibliographiccitation.lastpage","1940"],["dc.bibliographiccitation.volume","75"],["dc.contributor.author","Hijazi, Sameh"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Leitsmann, Conrad"],["dc.contributor.author","Strauss, A."],["dc.contributor.author","Meller, J."],["dc.contributor.author","Ritter, Christian Oliver"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Schildhaus, H.-U."],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.date.accessioned","2018-11-07T09:48:43Z"],["dc.date.available","2018-11-07T09:48:43Z"],["dc.date.issued","2015"],["dc.description.abstract","BACKGROUNDThe first evaluation of pelvic extended lymph node dissection (pLND) in oligometastatic prostate cancer (PCa) detected by Ga-68-PSMA PET/CT. METHODSRetrospective analysis of 35 PCa patients underwent Ga-68-PSMA PET/CT affected by biochemical recurrence (BCR) after curative treatment (n=23) or before primary therapy of high-risk PCa (n=12). We performed pLND associated with pathologic imaging in 17 men with nodal oligometastatic PCa. RESULTSIndicative lesions for PCa in PET/CT were detected in 91.4% (32 of 35) of patients. Nodal, bone, visceral (pulmonary), and within the prostate suspected disease were detected in 72% (23 of 32), 16% (5 of 32), 6% (2 of 32), and 47% (15 of 32) of patients, respectively. Median serum PSA in patients with pathological radiotracer uptake in recurrent and high-risk PCa patients was 2.9ng/ml (range 0.18-30) and 19.5ng/ml (range 6-90), respectively. The median number of removed lymph nodes with pLND in recurrent and high-risk PCa was 10 (range 4-17) and 12 (range 8-29) per patient and the median number of positive lymph nodes was 1 (range 1-2) and 3 (2-3) per patient, respectively. In total, two false positive and one false-negative lymph node were found. Diagnostic accuracies per nodal lesion in total of 213 removed nodes: sensitivity, 94%; specificity, 99%; positive predictive value (PPV), 89%, and negative predictive value (NPV), 99.5%. After pLND, 53% (9 of 17) of patients received androgen deprivation therapy and/or radiation therapy and hormonal therapy, while 47% (8 of 17) of patients remained free of any post-surgery therapy. Follow-up PSA remained less than 0.2ng/ml in 82% (14 of 17) of patients. After pLND, immediate BCR (PSA never measured less than 0.2ng/ml) in 18% (3 of 17) of patients was recorded. CONCLUSIONSThis represents the first study of pLND in the setting of nodal oligometastatic PCa detected by Ga-68-PSMA PET/CT. The use of Ga-68-PSMA PET/CT could be to improve the accuracy for the detection of nodal micrometastases. These promising findings need validation in larger studies. Prostate 75:1934-1940, 2015. (c) 2015 Wiley Periodicals, Inc."],["dc.identifier.doi","10.1002/pros.23091"],["dc.identifier.isi","000363219300013"],["dc.identifier.pmid","26356236"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35365"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1097-0045"],["dc.relation.issn","0270-4137"],["dc.title","Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by Ga-68-PSMA-positron emission tomography/computerized tomography"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","776"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","The Prostate"],["dc.bibliographiccitation.lastpage","780"],["dc.bibliographiccitation.volume","76"],["dc.contributor.author","Hijazi, Sameh"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Leitsmann, Conrad"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Ritter, Christian"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Meller, Johannis"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.date.accessioned","2018-11-07T10:14:00Z"],["dc.date.available","2018-11-07T10:14:00Z"],["dc.date.issued","2016"],["dc.description.abstract","BACKGROUNDOur study is the first evaluation of nodal metastatic prostate cancer (PCa) to mesorectal lymph nodes (MLN) detected by Ga-68-PSMA-PET/CT. METHODSWe retrospectively analyzed 76 consecutive PCa patients who underwent Ga-68-PSMA-PET/CT: 61 PCa patients with biochemical recurrence (BCR) after curative treatment and 15 high-risk PCa before primary therapy. We assessed PET-positive MLN, which are indicative for PCa. RESULTSWe detected PET-positive lesions for PCa in Ga-68-PSMA-PET/CT in 66 of 76 (87%) patients. Nodal disease was imaged in 47 of 66 (71%) patients. Indicative mesorectal nodal lesions for PCa were detected in 12 of 76 (15.8%) patients. The median number of PET-positive MLN was one per patient. Seven of twelve patients had recurrent PCa after radical prostatectomy with a median PSA value of 1.84ng/ml (range 0.31-13). Five of twelve patients had untreated first diagnosed high-risk PCa with median PSA value of 90ng/ml (range 4.6-93) at PET/CT, respectively. For all PET positive MLN a morphological correlate was found in CT (shortest diameter median 4mm [range 4-21]; longest diameter median 7.5mm [range 5-25]). After PET/CT, four patients with recurrent PCa received hormonal therapy, one patient was treated with directed radiation therapy of MLN, one patient received chemotherapy, and one patient was treated with pelvic lymph node dissection. Three high-risk PCa patients received hormonal therapy, and two patients were treated with adjuvant hormonal therapy after radical prostatectomy. CONCLUSIONSDetection and exact location of nodal metastasis for PCa is crucial for the choice of treatment and the patient's prognosis. Ga-68-PSMA-PET/CT seems to improve the detection of nodal metastasis in PCa, especially concerning mesorectal lymph nodes. Prostate 76:776-780, 2016. (c) 2016 Wiley Periodicals, Inc."],["dc.identifier.doi","10.1002/pros.23168"],["dc.identifier.isi","000374860200008"],["dc.identifier.pmid","26880517"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40540"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1097-0045"],["dc.relation.issn","0270-4137"],["dc.title","See the unseen: Mesorectal lymph node metastases in prostate cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2104"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Neurourology and Urodynamics"],["dc.bibliographiccitation.lastpage","2111"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Seseke, Sandra"],["dc.contributor.author","Leitsmann, Conrad"],["dc.contributor.author","Hijazi, Sameh"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Dechent, Peter"],["dc.date.accessioned","2020-12-10T14:07:00Z"],["dc.date.available","2020-12-10T14:07:00Z"],["dc.date.issued","2019"],["dc.description.abstract","AIMS: In recent years, the human brain-bladder control network has been visualized in different functional magnetic resonance imaging (fMRI) studies. The role of the brainstem and suprapontine regions has been elucidated. Especially the pontine region and the periaqueductal gray, as the central structures of the micturition circuit, were demonstrated. Detrusor sphincter dyssynergia (DSD) is a common problem in patients with neurological diseases. Residual urine and consecutive urinary tract infections with the risk of kidney damage remain a problem. In the present study, we used fMRI of the brain to compare the activation sites of patients with DSD with those of our previously published healthy controls with special emphasis on the brainstem region. METHODS: fMRI was performed in 11 patients with DSD who had an urge to void due to a filled bladder. In a nonvoiding model, they were instructed to contract or to relax the pelvic floor muscles repetitively. RESULTS: In patients with DSD, we could reproduce the activation sites found in healthy subjects, showing the regions in the brainstem as well as the other micturition-related areas. The activation of the pontine region was more rostral/dorsal compared with the healthy volunteers. CONCLUSION: Interestingly, we detected the well-known activation in the pontine region in the patients in the dorsal/rostral part compared with the more ventral activation in the healthy volunteers, suggesting that the L-region of the pontine micturition center is more prominent in cases of DSD."],["dc.identifier.doi","10.1002/nau.24112"],["dc.identifier.eissn","1520-6777"],["dc.identifier.issn","0733-2467"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16691"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70102"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.relation.eissn","1520-6777"],["dc.relation.issn","1520-6777"],["dc.relation.issn","0733-2467"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.subject.ddc","610"],["dc.title","Functional MRI in patients with detrusor sphincter dyssynergia: Is the neural circuit affected?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","898"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","European Journal of Nuclear Medicine and Molecular Imaging"],["dc.bibliographiccitation.lastpage","905"],["dc.bibliographiccitation.volume","43"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Bouter, Caroline"],["dc.contributor.author","Ritter, Christian Oliver"],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Hijazi, Sameh"],["dc.date.accessioned","2018-11-07T10:15:18Z"],["dc.date.available","2018-11-07T10:15:18Z"],["dc.date.issued","2016"],["dc.description.abstract","Purpose Binding of Ga-68-PSMA-HBED-CC (Ga-68-PSMA) at prostate cancer (PC) cells increases over time. A biphasic protocol may help separating benign from tumor lesions. The aim of this study was the retrospective evaluation of a diagnostic incremental value of a dual-time point (biphasic) Ga-68-PSMA-PET/CT in patients with prostate cancer. Methods Retrospective analysis of 35 consecutive patients (49-78 years, median 71) with newly diagnosed PC (12/35) or recurrence of PC (23/35). PET/CT (Gemini TF16, Philips) was acquired 1 h and 3 h p. i. of 140-392 MBq (300 MBq median) Ga-68-PSMA, followed by a diagnostic contrast CT. PET findings were correlated with histology or unequivocal CT findings. Semiquantitative PET data (SUVmax, SUV mean) were acquired and target-to-background-ratios (T/B-ratio) were calculated for benign and malign lesions for both time points. Size of lymph nodes (LN) on diagnostic CT was recorded. Statistical analysis was performed for assessment of significant changes of semiquantitative PET-parameters over time and for correlation of size and uptake of lymph nodes. Results One hundred and four lesions were evaluated. Sixty lesions were referenced by histology or unequivocal CT findings, including eight (13.3 %) histopathologically benign lymph nodes, 12 (20 %) histopathologically lymph node metastases, 12 (20 %) primary tumors, three (5 %) local recurrences, and 25 (41.7 %) bone metastases. Forty-four lesions were axillary LN with normal CT-appearance. Benign lesions had significantly lower SUVmax and T/B-ratios compared with malignant findings. Malign lesions showed a significant increase of both parameters over time compared to benign findings. There was no correlation between LN size and SUVmax. The sensitivity, specificity, the positive predictive value and negative predictive value of PET/CT regarding pelvic LN was 94 %, 99 %, 89 %, and 99.5 %, respectively. Conclusions In contrast to benign tissues, the uptake of proven tumor lesions increases on Ga-68-PSMA-PET/CT over time. A biphasic PET-study may lead to a better detection of tumor lesions in unequivocal findings."],["dc.identifier.doi","10.1007/s00259-015-3251-y"],["dc.identifier.isi","000373306800012"],["dc.identifier.pmid","26563122"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40786"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1619-7089"],["dc.relation.issn","1619-7070"],["dc.title","Biphasic Ga-68-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]